Back to Search Start Over

Baseline serum HE4 but not tissue HE4 expression predicts response to the levonorgestrel-releasing intrauterine system in atypical hyperplasia and early stage endometrial cancer

Authors :
Y Louise Wan
Roya Behrouzi
Chloe E Barr
Emma J Crosbie
Rhona J McVey
Zoe Maskell
Neil A J Ryan
Katie Stocking
James Bolton
Abigail E. Derbyshire
Philip W. Pemberton
Source :
Behrouzi, R, Ryan, N, Barr, C, Derbyshire, A, Wan, L, Maskell, Z, Stocking, K, Pemberton, P, Bolton, J, McVey, R J & Crosbie, E 2020, ' Baseline serum HE4 but not tissue HE4 expression predicts response to the levonorgestrel-releasing intrauterine system in atypical hyperplasia and early stage endometrial cancer ', Cancers . https://doi.org/10.3390/cancers12020276, Cancers, Behrouzi, R, Ryan, N A J, Barr, C E, Derbyshire, A E, Wan, Y L, Maskell, Z, Stocking, K, Pemberton, P W, Bolton, J, McVey, R J & Crosbie, E J 2020, ' Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer ', Cancers, vol. 12, no. 2 . https://doi.org/10.3390/cancers12020276, Cancers, Vol 12, Iss 2, p 276 (2020), Volume 12, Issue 2
Publication Year :
2020

Abstract

The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE4 expression could predict response to LNG-IUS therapy. Patients with AH or presumed Stage I EEC had serum and endometrial samples taken at baseline and at 3-month intervals over 12 months post-insertion of LNG-IUS. 74 patients were recruited and baseline demographics recorded. Of 57 patients for whom response was histologically determinable, 39 (68%) were responders and 18 (32%) non-responders. Mean baseline serum HE4 was significantly lower in responders (62.1 &plusmn<br />1.1 pM, 95% confidence interval (CI) 52.7&ndash<br />73.2), compared to non-responders (125.6 &plusmn<br />1.3 pM, 95% CI 74.5&ndash<br />211.7, p = 0.014), including when considering age, BMI, menopausal status, smoking status, and histological grade as covariables (p = 0.005). Baseline tissue HE4 expression was not significantly different in responders compared to non-responders (p = 0.999). Responders showed a significant mean reduction (&minus<br />9.8 &plusmn<br />3.4%, 95% CI &minus<br />16.7 to &minus<br />2.8%, p = 0.008) in serum HE4 between baseline and 3 months (p = 0.008), whereas non-responders showed no significant change (p = 0.676). Neither responders nor non-responders showed a significant percentage change in serum HE4 from baseline beyond 3 months (p &gt<br />0.05). Change in serum HE4 between baseline and 3 and 6 months and tissue HE4 tissue expression between baseline and 3, 6, and 12 months was not significantly different in responders compared to non-responders (p &gt<br />0.05). This study suggests that baseline serum HE4, but not baseline tissue HE4 expression, is independently predictive of response to the LNG-IUS and could be used to guide management decisions.

Details

Language :
English
Database :
OpenAIRE
Journal :
Behrouzi, R, Ryan, N, Barr, C, Derbyshire, A, Wan, L, Maskell, Z, Stocking, K, Pemberton, P, Bolton, J, McVey, R J & Crosbie, E 2020, ' Baseline serum HE4 but not tissue HE4 expression predicts response to the levonorgestrel-releasing intrauterine system in atypical hyperplasia and early stage endometrial cancer ', Cancers . https://doi.org/10.3390/cancers12020276, Cancers, Behrouzi, R, Ryan, N A J, Barr, C E, Derbyshire, A E, Wan, Y L, Maskell, Z, Stocking, K, Pemberton, P W, Bolton, J, McVey, R J & Crosbie, E J 2020, ' Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer ', Cancers, vol. 12, no. 2 . https://doi.org/10.3390/cancers12020276, Cancers, Vol 12, Iss 2, p 276 (2020), Volume 12, Issue 2
Accession number :
edsair.doi.dedup.....7369e016706a52ad14911956f2ea52b2
Full Text :
https://doi.org/10.3390/cancers12020276